**Table 1: The demographic characteristics of the cases**

|  |  |  |
| --- | --- | --- |
|  | **n** | **%** |
| **Sex** | | |
| Female | 136 | 47,1 |
| Male | 153 | 52,9 |
| **Age (year)** | | |
| Mean ± SD (min-max) | 13,5 ± 5,1 (1-24) | |
| **Epilepsy type** | | |
| Unknown | 3 | 1,0 |
| Focal Epilepsy | 70 | 24,2 |
| Generalized + Focal Epilepsy | 89 | 30,8 |
| Generalized Epilepsy | 127 | 43,9 |
| **Age at diagnosis of epilepsy (months)** | | |
| Mean ± SD (min-max) | 4,0 ± 4,7 (0,12-36) | |
| **Number of ASMs used** | | |
| Mean ± SD (min-max) | 2,9 ± 1,1 (1-6) | |
| **Lacosamide starting age (year)** | | |
| Mean ± SD (min-max) | 10,5 ± 4,7 (1-21) | |
| **Lacosamide starting dose (mg/kg/g)** | | |
| Mean ± SD (min-max) | 2,7 ± 1,2 (0,5-7) | |
| Lacosamide time to effective dose (months) | | |
| Mean ± SD (min-max) | 2,1 ± 2,3 (0-16) | |
| **Number of ASMs** | | |
| None | |  |  | | --- | --- | | 2 | 0,7 | | |
| 1-3 drugs | |  |  | | --- | --- | | 210 | 72,7 | | |
| 4-6 drugs | |  |  | | --- | --- | | 75 | 26,0 | | |
| 7 drugs and more | |  |  | | --- | --- | | 2 | 0,7 | | |
| **Concomitant use of Na channel blocker drugs** | | |
| Yes | |  |  | | --- | --- | | 145 | 50,2 | | |
| No | |  |  | | --- | --- | | 144 | 49,8 | | |

\*ASMs: Anti-seizures medication

**Table 2: Effect of lacosamide treatment on seizure frequency**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Seizure frequency after Lacosamide treatment** | | | | | | **p value \*** |
| **Seizure frequency before Lacosamide treatment** | **Everyday** | **More than once a week** | **Once a week** | **More than once per month** | **Once in a month** | **Total** |
| **Everyday** | 74 | 28 | 8 | 5 | 12 | 127 | **<0,001** |
| **More than once a week** | 2 | 45 | 13 | 18 | 21 | 99 |
| **Once a week** | 0 | 2 | 5 | 5 | 4 | 17 |
| **More than once per month** | 0 | 0 | 0 | 0 | 26 | 35 |
| **Once in a month** | 0 | 0 | 0 | 0 | 11 | 11 |
| **Total** | 76 | 75 | 26 | 38 | 74 | 289 |
| \*McNemar-Bowker Test | | | | | | | |

**Table 3: TEAEs in the cases and their frequency**

|  |  |  |
| --- | --- | --- |
| **TEAE** | **n** | **%** |
| **Somnolence** | 30 | 43.5 |
| **Behavior change** | 9 | 13.0 |
| **Unrest** | 8 | 11.6 |
| **Dizziness** | 6 | 8.7 |
| **Abdominal pain, vomiting** | 3 | 4.3 |
| **Skin reaction** | 3 | 4.3 |
| **Leukopenia, thrombocytopenia** | 3 | 4.3 |
| **Cerebellar findings**  **(Tremor, nystagmus, ataxia)** | 3 | 4.3 |
| **Increased myoclonia** | 1 | 1.4 |
| **Increased appetite** | 1 | 1.4 |
| **Hypersalivation** | 1 | 1.4 |
| **Suicide attempt** | 1 | 1.4 |
| **Total** | 69 | 100 |